von Moltke Lisa's Insider Trades & SAST Disclosures
von Moltke Lisa's most recent trade in Seres Therapeutics Inc was a trade of 8,907 Common Stock done . Disclosure was reported to the exchange on Feb. 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern von Moltke Lisa.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 8,907 | 44,291 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 8,907 | 26,718 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | Sale of securities on an exchange or to another person at price $ 0.81 per share. | 15 Feb 2025 | 4,416 | 39,875 (0%) | 0% | 0.8 | 3,579 | Common Stock |
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 2,969 | 23,750 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 2,969 | 35,384 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 650,000 | 650,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 15 Nov 2024 | 2,969 | 26,719 | - | - | Restricted Stock Units | ||
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 15 Nov 2024 | 2,969 | 33,392 (0%) | 0% | - | Common Stock | ||
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 15 Nov 2024 | 977 | 32,415 (0%) | 0% | 0.5 | 528 | Common Stock | |
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 27 Oct 2024 | 13,744 | 0 | - | - | Restricted Stock Units | ||
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 27 Oct 2024 | 13,744 | 34,757 (0%) | 0% | 0 | Common Stock | ||
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 27 Oct 2024 | 4,334 | 30,423 (0%) | 0% | 0.7 | 2,991 | Common Stock | |
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 15 Aug 2024 | 2,969 | 29,688 | - | - | Restricted Stock Units | ||
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 15 Aug 2024 | 2,969 | 21,986 (0%) | 0% | - | Common Stock | ||
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 15 Aug 2024 | 973 | 21,013 (0%) | 0% | 0.8 | 817 | Common Stock | |
| Tvardi Therapeutics Inc. | Lisa von Moltke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 195,000 | 195,000 | - | - | Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc. | Lisa von Moltke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 150,647 | 183,009 (0%) | 0% | 0 | Common Stock | |
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 14 May 2024 | 2,968 | 32,657 | - | - | Restricted Stock Units | ||
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 14 May 2024 | 2,968 | 19,956 (0%) | 0% | - | Common Stock | ||
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 14 May 2024 | 939 | 19,017 (0%) | 0% | 0.9 | 883 | Common Stock | |
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 14 Feb 2024 | 287,905 | 287,905 | - | - | Stock Option (Right to Buy) | ||
| Seres Therapeutics Inc | von Moltke Lisa | See Remarks | 14 Feb 2024 | 213,750 | 213,750 | - | - | Stock Option (Right to Buy) | ||
| Seres Therapeutics Inc | von Moltke Lisa | See Remarks | 14 Feb 2024 | 35,625 | 35,625 | - | - | Restricted Stock Units | ||
| Seres Therapeutics Inc | von Moltke Lisa | See Remarks | 14 Feb 2024 | 11,875 | 35,625 | - | - | Restricted Stock Units | ||
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 14 Feb 2024 | 11,875 | 21,388 (0%) | 0% | - | Common Stock | ||
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 14 Feb 2024 | 4,400 | 16,988 (0%) | 0% | 1.1 | 4,752 | Common Stock | |
| Tvardi Therapeutics Inc. | Lisa von Moltke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 44,961 | 44,961 | - | - | Stock Option (Right to Buy) | |
| Tvardi Therapeutics Inc. | Lisa von Moltke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 32,362 | 32,362 (0%) | 0% | 0 | Common Stock | |
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 03 Feb 2023 | 95,000 | 95,000 | - | - | Stock Option (Right to Buy) | ||
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 03 Feb 2023 | 47,500 | 47,500 | - | - | Restricted Stock Units | ||
| Tvardi Therapeutics Inc. | Lisa von Moltke | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2023 | 45,841 | 45,841 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 04 Feb 2022 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | ||
| Seres Therapeutics Inc | Lisa von Moltke | See Remarks | 04 Feb 2021 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges